Item 8.01. Other Events. Reference is hereby made to: (a) the registration statement of Lineage Cell Therapeutics, Inc. (the “Company”) on Form S-3 (File No. 333-254167), registering the offer and sale of up to $75,000,000 of any combination of the Company’s common shares, preferred shares, debt securities and warrants, which was declared effective on March 19, 2021 (the “Registration Statement”); and (b) the prospectus supplement dated May 18, 2023, which was filed with the U.S. Securities and Exchange Commission (the “Commission”) pursuant to Rule 424(b)(5) on May 18, 2023, which updates, amends and supplements the prospectus supplement filed with the Commission on December 21, 2023 for th(…)
The Latest Press Releases